Cover Image
市場調查報告書

腹膜癌:開發中產品分析

Peritoneal Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229745
出版日期 內容資訊 英文 676 Pages
訂單完成後即時交付
價格
Back to Top
腹膜癌:開發中產品分析 Peritoneal Cancer - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 676 Pages
簡介

所謂腹膜癌是由腹膜發病的罕見癌症。腹膜是覆蓋於腹壁的薄膜,範圍廣及子宮到膀胱、直腸。腹膜癌一般會造成腹部腫脹、伴隨腹水的廣域性非特異性腹痛。常見的症狀有呼吸急促、直腸出血、食慾不振、頻尿、便秘、噁心、腹瀉,(即使只用輕食後)滿腹感等。主要的治療方法包含了化療、外科手術、生物學療法、放射線治療等。

本報告提供腹膜癌的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

腹膜癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

腹膜癌:企業開發中的治療藥

腹膜癌:大學/機關研究中的治療藥

腹膜癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

腹膜癌:企業開發中的產品

腹膜癌:大學/機關研究中的產品

腹膜癌的治療藥的開發企業

  • AbbVie Inc.
  • Acetylon Pharmaceuticals, Inc.
  • Adaptimmune Therapeutics Plc
  • Aduro BioTech, Inc.
  • Advanced Accelerator Applications SA
  • Advenchen Laboratories, LLC
  • Amgen Inc.
  • Array BioPharma Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Atara Biotherapeutics, Inc.
  • AVEO Pharmaceuticals, Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Caladrius Biosciences, Inc.
  • Celldex Therapeutics, Inc.
  • Celsion Corporation
  • CerRx, Inc.
  • Cerulean Pharma, Inc.
  • Clovis Oncology, Inc.
  • Corcept Therapeutics Incorporated
  • Critical Outcome Technologies Inc.
  • CritiTech, Inc.
  • CTI BioPharma Corp.
  • Dr. Reddy's Laboratories Limited
  • EirGenix Inc.
  • Eli Lilly and Company
  • Epirus Biopharmaceuticals, Inc.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Galena Biopharma, Inc.
  • Ganymed Pharmaceuticals AG
  • Genelux Corporation
  • Genentech, Inc.
  • Genor BioPharma Co., Ltd.
  • Glycotope GmbH
  • Gradalis Inc.
  • Hemispherx Biopharma, Inc.
  • ImmunoGen, Inc.
  • Immunovaccine, Inc.
  • Incyte Corporation
  • Innate Pharma S.A.
  • Johnson & Johnson
  • Juno Therapeutics Inc.
  • Kyowa Hakko Kirin
  • Lee's Pharmaceutical Holdings Limited
  • Mabion SA
  • MabVax Therapeutics Holdings, Inc.
  • MedImmune, LLC
  • Medivation, Inc.
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • MolMed S.p.A.
  • Mycenax Biotech Inc.
  • Novartis AG
  • Oasmia Pharmaceutical AB
  • OBI Pharma, Inc.
  • Oncobiologics, Inc.
  • Oncolix, Inc.
  • Oncolytics Biotech Inc.
  • OncoMed Pharmaceuticals, Inc.
  • 小野藥品工業
  • Oxford BioMedica Plc
  • OXiGENE, Inc.
  • Pharma Mar, S.A.
  • Pharmacyclics, Inc.
  • PsiOxus Therapeutics Limited
  • Quest PharmaTech Inc.
  • Sanofi Pasteur SA
  • Shenzen SiBiono GeneTech Co., Ltd.
  • Sotio a.s.
  • Synta Pharmaceuticals Corp.
  • TapImmune Inc.
  • Tesaro, Inc.
  • TetraLogic Pharmaceuticals
  • Tyrogenex, Inc.
  • Vascular Biogenics Ltd.
  • VentiRx Pharmaceuticals, Inc.

腹膜癌:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

腹膜癌:最近的開發平台趨勢

腹膜癌:暫停中的計劃

腹膜癌:開發中止的產品

腹膜癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8470IDB

Summary

Global Markets Direct's, 'Peritoneal Cancer - Pipeline Review, H2 2016', provides an overview of the Peritoneal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peritoneal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer
  • The report reviews pipeline therapeutics for Peritoneal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Peritoneal Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Peritoneal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Peritoneal Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Peritoneal Cancer Overview
  • Therapeutics Development
  • Peritoneal Cancer - Therapeutics under Development by Companies
  • Peritoneal Cancer - Therapeutics under Investigation by Universities/Institutes
  • Peritoneal Cancer - Pipeline Products Glance
  • Peritoneal Cancer - Products under Development by Companies
  • Peritoneal Cancer - Products under Investigation by Universities/Institutes
  • Peritoneal Cancer - Companies Involved in Therapeutics Development
  • Peritoneal Cancer - Therapeutics Assessment
  • Drug Profiles
  • Peritoneal Cancer - Dormant Projects
  • Peritoneal Cancer - Discontinued Products
  • Peritoneal Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Peritoneal Cancer, H2 2016
  • Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Peritoneal Cancer - Pipeline by AbbVie Inc, H2 2016
  • Peritoneal Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
  • Peritoneal Cancer - Pipeline by Aduro BioTech, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Advanced Accelerator Applications S.A., H2 2016
  • Peritoneal Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016
  • Peritoneal Cancer - Pipeline by Amgen Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by AstraZeneca Plc, H2 2016
  • Peritoneal Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Bayer AG, H2 2016
  • Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Peritoneal Cancer - Pipeline by Boston Biomedical, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Celsion Corporation, H2 2016
  • Peritoneal Cancer - Pipeline by CerRx, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Clovis Oncology, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2016
  • Peritoneal Cancer - Pipeline by CritiTech, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by CTI BioPharma Corp., H2 2016
  • Peritoneal Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
  • Peritoneal Cancer - Pipeline by EirGenix Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Eisai Co., Ltd., H2 2016
  • Peritoneal Cancer - Pipeline by Eli Lilly and Company, H2 2016
  • Peritoneal Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Exelixis, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Peritoneal Cancer - Pipeline by Galena Biopharma, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2016
  • Peritoneal Cancer - Pipeline by Gene Techno Science Co., Ltd., H2 2016
  • Peritoneal Cancer - Pipeline by Genelux Corporation, H2 2016
  • Peritoneal Cancer - Pipeline by Genentech, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2016
  • Peritoneal Cancer - Pipeline by Glycotope GmbH, H2 2016
  • Peritoneal Cancer - Pipeline by Gradalis Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Hemispherx Biopharma, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by ImmunoGen, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Immunovaccine, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Incyte Corporation, H2 2016
  • Peritoneal Cancer - Pipeline by Innate Pharma S.A., H2 2016
  • Peritoneal Cancer - Pipeline by Johnson & Johnson, H2 2016
  • Peritoneal Cancer - Pipeline by Juno Therapeutics Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
  • Peritoneal Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
  • Peritoneal Cancer - Pipeline by Mabion SA, H2 2016
  • Peritoneal Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Mateon Therapeutics Inc, H2 2016
  • Peritoneal Cancer - Pipeline by MedImmune, LLC, H2 2016
  • Peritoneal Cancer - Pipeline by Medivation, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Merck & Co., Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Merck KGaA, H2 2016
  • Peritoneal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Peritoneal Cancer - Pipeline by MolMed S.p.A., H2 2016
  • Peritoneal Cancer - Pipeline by Mycenax Biotech Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Neopharm Ltd., H2 2016
  • Peritoneal Cancer - Pipeline by Novartis AG, H2 2016
  • Peritoneal Cancer - Pipeline by OBI Pharma, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Oncobiologics, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Oncolix, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016
  • Peritoneal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Peritoneal Cancer - Pipeline by Oxford BioMedica Plc, H2 2016
  • Peritoneal Cancer - Pipeline by Pharma Mar, S.A., H2 2016
  • Peritoneal Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2016
  • Peritoneal Cancer - Pipeline by Quest PharmaTech Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Richter Gedeon Nyrt., H2 2016
  • Peritoneal Cancer - Pipeline by Samyang Holdings Corporation, H2 2016
  • Peritoneal Cancer - Pipeline by Sanofi Pasteur SA, H2 2016
  • Peritoneal Cancer - Pipeline by Sotio a.s., H2 2016
  • Peritoneal Cancer - Pipeline by TapImmune Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016
  • Peritoneal Cancer - Pipeline by Tesaro, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2016
  • Peritoneal Cancer - Pipeline by Tyrogenex, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Vascular Biogenics Ltd., H2 2016
  • Peritoneal Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016
  • Peritoneal Cancer - Pipeline by Vyriad, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Peritoneal Cancer - Dormant Projects, H2 2016
  • Peritoneal Cancer - Dormant Projects (Contd..1), H2 2016
  • Peritoneal Cancer - Dormant Projects (Contd..2), H2 2016
  • Peritoneal Cancer - Dormant Projects (Contd..3), H2 2016
  • Peritoneal Cancer - Dormant Projects (Contd..4), H2 2016
  • Peritoneal Cancer - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Peritoneal Cancer, H2 2016
  • Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top